Piper Sandler raised the firm’s price target on NeoGenomics (NEO) to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics to present RaDaR ST bridging study at ISLB 2025
- NeoGenomics price target raised to $11 from $6.50 at BofA
- NeoGenomics Reports Strong Revenue Growth Amid Rising Losses
- NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges
- Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target